Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conivaptan Infusion and Exercise Hemodynamics in Heart Failure
2012-003219-77Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of conivaptan in heart failure (HF), sponsored by Rigshospitalet. Primary endpoint: Pulmonary capillary wedge pressure at 50% maximal exercise intensity. Started Dec 2012; status: completed.
02
Drugs
conivaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2012-003219-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003219-77.